Skip to main content

Basel, Switzerland – 9 Jan, 2025, Alentis Therapeutics, a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced positive topline results from two clinical trials of lixudebart (ALE.F02), a monoclonal antibody targeting Claudin-1 (CLDN1), developed to reverse organ fibrosis.

Lixudebart was investigated in two double-blind, placebo-controlled, randomized studies. RENAL-F02 is an ongoing Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV) with Rapidly Progressive Glomerulonephritis (RPGN) (NCT06047171), where 26 patients have been dosed for up to 24 weeks. FEGATO-01 is a Phase 1b clinical trial where 41 patients with mainly advanced F3/F4 liver fibrosis and/or mild cirrhosis were dosed for up to 4 weeks (NCT05939947).

The results from the two studies are very encouraging, particularly given the dose-dependent target engagement and favorable safety profile. We also observed an initial decrease in ALT/AST in liver fibrosis patients treated with lixudebart.

Dr. Luigi ManentiChief Medical Officer at Alentis

Read more here.

Share this article

View all news

Sign up to receive our newsletter in your inbox.